If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an exclusive analyst call entitled What Impact Will the Emergence of Herceptin and Other Targeted Therapies Have on the Gastric Cancer Drug Market? News from ASCO. Because this presentation will feature updates to the Gastric Cancer topic, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Clinical trial data regarding Roche/Genentech/Chugai’s Avastin that was presented earlier this month at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting confirms Decision Resources’ forecast for this key agent in the gastric cancer drug market. Additionally, in response to the European approval and market entry of Roche/Genentech/Chugai’s Herceptin, a HER2-directed therapeutic agent, we have segmented the unresectable gastric cancer patient population by HER2 status in order to better shape our market forecast for this indication. The rapid and widespread uptake of Herceptin and the emergence of four targeted therapies will drive the gastric cancer drug market to more than double to $1.5 billion from 2009 to 2019. This 15-minute analyst call, presented by Decision Resources Analyst Rachel Webster, D.Phil., will answer the following questions:
Dr. Webster will conduct a live Q & A session after the presentation. Registration What Impact Will the Emergence of Herceptin and Other Targeted Therapies Have on the Gastric Cancer Drug Market? News from ASCO June 28, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Rachel Webster, M.Sc., D. Phil., is a research analyst in the oncology department at Decision Resources. Prior to joining the company, Dr. Webster was a research scientist at Immunocore (formerly MediGene) in the phage display and protein engineering group. Dr. Webster also worked at Cybersense Biosystems, where her research involved molecular engineering of bacterial membrane receptors and signal transduction pathways for the construction of a biosensor. Dr. Webster obtained her D.Phil. and M.Sc. in biochemistry and biological sciences, respectively, from the University of Oxford.